Navigation Links
Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says
Date:11/11/2008

obial stewardship programs with focus on restriction of antibiotics associated with CDI and unnecessary antimicrobial use. APIC's evidence-based elimination guides translate CDC recommendations into practice.

"Healthcare providers must intensify efforts toward developing prevention strategies that can be consistently applied across the continuum of care," said APIC CEO Kathy L. Warye. "Control of CDI requires adequate numbers of infection preventionists and environmental services personnel, and prevention practices need to be part of everyone's job within the institution. As part of our Targeting Zero initiative, APIC will continue to call for the commitment of clinical and administrative leadership to providing adequate resources for infection prevention programs to better protect patients in our nation's healthcare facilities."

The APIC National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities will be published in the American Journal of Infection Control. For more information about the study, visit http://www.apic.org.

APIC's mission is to improve health and patient safety by reducing risks of infection and other adverse outcomes. The association's 12,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities around the globe. APIC advances its mission through education, research, collaboration, practice guidance, public policy and credentialing. Visit APIC online at http://www.apic.org


'/>"/>
SOURCE Association for Professionals in Infection Control andEpidemiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Irritable Bowel Syndrome Takes Center Stage at Yakults 17th Intestinal Flora Symposium
2. Strategies for preventing gastrointestinal complications in severely burned patients
3. Pneumatosis cystoids intestinalis after fluorouracil chemotherapy
4. A new breakthrough in timing of urgent endoscopy for gastrointestinal bleeding patients
5. Ben-Gurion University of the Negev initiates project to eliminate intestinal worms in Ethiopia
6. Intestinal Gluten Receptor Is Gateway for Celiac Disease
7. July 2008 Mayo Clinic Womens HealthSource Highlights Vitamin D, Savvy Use of Sunscreen and Gastrointestinal Upset and Celiac Disease
8. Medical check-ups for intestinal cancer are hardly used
9. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
10. Discovery of new family of genetic mutations involved in inflammatory intestinal disease
11. Protein predicts Gleevec resistance in gastrointestinal tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
(Date:7/23/2014)... together for the first time to call for better ... worldwide suffering from the condition. , Psoriatic arthritis (PsA) ... damage if left untreated. , PsA tends to affect ... red, scaly rash, and affects approximately two per cent ... in five go on to develop PsA usually ...
(Date:7/23/2014)... Louis (PRWEB) July 23, 2014 Five years ... its doors there were few options for babies diagnosed with ... delivery, or travel across the country for innovative fetal therapies. ... Fetal Care Institute to care for their babies in the ... surgeries and interventions. , “A number of the babies ...
(Date:7/23/2014)... models of human oral cancer treated with an agent ... surrounding tissues, researchers from the School of Dentistry and ... Science Center at San Antonio found. The Health Science ... study, which is described in the journal Oral ... , Oral squamous cell carcinoma is the eighth most ...
(Date:7/23/2014)... July 23, 2014 SpaRoom® ... SpaRoom’s top product and premier diffuser, is now available ... and an improved motor for maximum quality. The new ... now available on SpaRoom.com for $60 along with the ... ultrasonic pulsations to create a long-lasting, tranquil mist. Add ...
Breaking Medicine News(10 mins):Health News:Psoriatic arthritis patients need better screening, warns panel of experts 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2
... to The Diabetes Research Institute of Miami on ... behalf of the motorcycle franchisee, ... check to The Diabetes Research Institute of Miami in honor ... the,leading voluntary insurer announced the motorcycle franchisee as its,100,000th Online ...
... epilepsy and depression, researchers say , , FRIDAY, ... deep brain stimulation sensor that can monitor levels ... Clinic researchers and colleagues. , The wireless instantaneous ... the brain to provide real-time measurement of chemicals ...
... Local Patients May Be at,Risk, PHILADELPHIA, Sept. 12 ... blood supply alert for New Jersey and,southeastern Pennsylvania., ... critical need for Type O,blood. Brigid O,Neill-LaGier, Chief Executive ... the community to donate blood. "The blood,supply is a ...
... reports a hiring trend over the past four months within High-Tech ... is has become a “recruiters” market causing both parties to change ... ... 2008 -- Lucas Group, an executive search firm, today reports a ...
... yearn to wear the sheer, body-hugging fashions available today, we ... dreaded back fat rolls and lumps. A study published in ... the official medical journal of the American Society of Plastic ... these unsightly bumps and bulges while hiding the scar under ...
... ATSI ), manufacturer and marketer of state-of-the-art ... unprecedented number,of scientific presentations and symposia will focus ... for Cardio-Thoracic Surgeons (EACTS),meeting. The EACTS is a ... and is being held in Lisbon, Portugal from ...
Cached Medicine News:Health News:Aflac Celebrates With Peterson's Harley Davidson of Miami as 100,000th Online Billing Customer 2Health News:American Red Cross Issues Local Blood Supply Alert 2Health News:American Red Cross Issues Local Blood Supply Alert 3Health News:Lucas Group Reports Hiring Trend in High-Tech Medical Device 2Health News:Say 'goodbye' to back fat rolls 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 3Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 4
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/22/2014)... TOKYO , July 23, 2014   ... Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a ... the company will be investing US$30 million in Remiges ... venture capital fund. Taiho has a long ... needs of oncologists and cancer patients. Our development of ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2
... Abbott (NYSE: ABT ) scientists and independent researchers ... Abbott,s investigational oncology compounds at this year,s American Society ... June 4-8 in Chicago . The presentations include ... and a humanized monoclonal antibody directed against CS1. Abbott,s oncology ...
... EAST HANOVER, N.J. , June 3 ... study of Afinitor® (everolimus) tablets plus best supportive care met ... or time without tumor growth, in patients with advanced pancreatic ... I n A dvanced N euroendocrine T ...
Cached Medicine Technology:Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 7Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 2Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 3Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 4Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 5Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 6Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 7
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: